Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
2216-51-5
Molecular formula
C10H20O
Molecular weight
156.2652 g/mol
Drug class
Topical counterirritant and local cooling agentTRPM8 agonist
Mechanism of action
Activates cold-sensitive transient receptor potential melastatin-8 (TRPM8) channels in cutaneous sensory nerves, producing a cooling sensation. Counter-irritant and sensory-modulating effects can reduce perception of local pain or discomfort.
Indications / reported uses
Topical relief of headache with authorised cutaneous formulations.
Symptomatic relief of nasal congestion and common-cold symptoms with authorised nasal preparations.
Topical relief of minor muscle and joint pain in appropriate combination products.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Levomenthol Environmental Risk Assessment (ERA) (the Levomenthol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.